SEPN Stock Summary and Trading Ideas (Septerna | NASDAQ:SEPN)

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Septerna trades on the NASDAQ stock market under the symbol SEPN.

As of November 6, 2026, SEPN stock price climbed to $48.85 with 372,388 million shares trading.

SEPN has a beta of 0.71, meaning it tends to be less sensitive to market movements. SEPN has a correlation of 0.02 to the broad based SPY ETF.

SEPN has a market cap of $2.28 billion. This is considered a Mid Cap stock.

Last quarter Septerna reported $27 million in Revenue and -$.29 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.20.

The top ETF exchange traded funds that SEPN belongs to (by Net Assets): VTI, IWM, XPH, IBB, VXF.

SEPN has outperformed the market in the last year with a price return of +159.8% while the SPY ETF gained +10.8%. SEPN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +23.6% and +20.9%, respectively, while the SPY returned -4.1% and -3.2%, respectively.

SEPN support price is $45.32 and resistance is $49.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SEPN shares will trade within this expected range on the day.